Proteomics International Laboratories

Proteomics International Laboratories Net Margin

The Net Profit Margin of Proteomics International Laboratories (PIQ.AX) as of Oct 28, 2026 is -3,078.86 %. In the previous year, Net Profit Margin was -844.95 % — a change of 264.38% (lower).

Net Margin

-3,078.86 %

YoY

264.38%

Last updated:

Net Profit Margin of Proteomics International Laboratories is 2026 -3,078.86 % . Net Profit Margin of Proteomics International Laboratories was 2025 -844.95 % . It decreases by 264.38% lower compared to the previous year.

Proteomics International Laboratories's net margin stands at -3,078.9%, down from -333.9% several years earlier.

The Proteomics International Laboratories Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2019
-141.70 AUD
Jan 1, 2020
-122.54 AUD
Jan 1, 2021
-218.16 AUD
Jan 1, 2022
-333.91 AUD
Jan 1, 2023
-853.62 AUD
Jan 1, 2024
-714.71 AUD
Jan 1, 2025
-844.95 AUD
Jan 1, 2026
-3,078.86 AUD
The Proteomics International Laboratories Net Margin history
YEARNet MarginYoY
-3,078.86 %+264.38%
-844.95 %+18.22%
-714.71 %-16.27%
-853.62 %+155.64%
-333.91 %+53.06%
-218.16 %+78.04%
-122.54 %-13.52%
-141.70 %+15.76%
-122.41 %+23.60%
-99.04 %-39.10%
-162.63 %-13.90%
-188.89 %+764.35%
-21.85 %+11,389.76%
-0.19 %-29.19%
-0.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Proteomics International Laboratories Stock analysis

What does Proteomics International Laboratories do? Proteomics International Laboratories Ltd is a medical technology company based in Nedlands, Western Australia, listed on the stock exchange in April 2015. Operating within the health care sector, the firm specializes in predictive diagnostics and bio-analytical services, focusing on the study of protein structure and function. It develops and commercializes diagnostic tests for chronic diseases, particularly diabetic kidney disease. The company operates three unified business units: PromarkerD, which offers a blood test to assess DKD risk in type 2 diabetes patients; Diagnostics, which utilizes the Promarker platform to discover and validate protein biomarkers; and Analytical Services, which employs a proteomics-based technology platform to test and validate the protein composition of various products. Proteomics International Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Proteomics International Laboratories stock

Net Profit Margin of Proteomics International Laboratories is -3,078.86 % in 2026.

Net Profit Margin of Proteomics International Laboratories changed from -844.95 % to -3,078.86 %, representing a 264.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Proteomics International Laboratories since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Proteomics International Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Proteomics International Laboratories

All Key Metrics — Proteomics International Laboratories